(1R,2S)-VU0155041

CAS No. 1263273-14-8

(1R,2S)-VU0155041( —— )

Catalog No. M26526 CAS No. 1263273-14-8

(1R,2S)-VU0155041 is a partial agonist of mGluR4(EC50 of 2.35 μM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 37 Get Quote
5MG 60 Get Quote
10MG 88 Get Quote
25MG 195 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    (1R,2S)-VU0155041
  • Note
    Research use only, not for human use.
  • Brief Description
    (1R,2S)-VU0155041 is a partial agonist of mGluR4(EC50 of 2.35 μM).
  • Description
    (1R,2S)-VU0155041 is a partial agonist of mGluR4(EC50 of 2.35 μM).(In Vitro):(1R,2S)-VU0155041 is similar in potency with VU0155041 At both human and rat receptors (798 nM at human mGluR4 and 693 nM at rat mGluR4). (1R,2S)-VU0155041 (30 μM) induces concentration-dependent shifts in the baseline when examined in fold shift experiments using the thallium flux assay.
  • In Vitro
    At both human and rat receptors, the Cis regioisomer of VU0155041 is similar in potency (798±58 nM at human mGluR4 and 693±140 nM at rat mGluR4). Conversely, the concentration-response curve for the Trans regioisomer (VU0155040) does not plateau at the maximum concentration tested. Fold-shift experiments at 30 μM of VU0155041 also shows that the Cis regioisomer is more effective at this concentration on both human and rat mGluR4. VU0155041, induces concentration-dependent shifts in the baseline when examined in fold shift experiments using the thallium flux assay. VU0155041 induces a response that reaches approximately 45% of the maximal glutamate response. VU0155041is a partial agonist of mGluR4 that activates the receptor by interacting with a site that is distinct from the glutamate binding site. VU0155041 exhibitsselectivity for mGluR4 relative to 67 different targets and does not affect the function of striatal NMDA receptors.
  • In Vivo
    VU0155041 is soluble in an aqueous vehicle and intracerebroventricular administration of 31 to 316 nM of VU0155041 dose-dependently decreases haloperidol-induced catalepsy and reserpine-induced akinesia in rats. VU0155041, at doses of 31 and 92 nmol, is also able to significantly decrease the cataleptic effects of haloperidol, and the effects of the compound are still present 30 min after infusion. Icv infusion of a 316 nmol dose of VU0155041 also results in a significant reversal of akinesia.
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    ROCK
  • Recptor
    TRPM3
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1263273-14-8
  • Formula Weight
    316.18
  • Molecular Formula
    C14H15Cl2NO3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (158.14 mM)
  • SMILES
    O=C([C@H]1[C@@H](C(NC2=CC(Cl)=CC(Cl)=C2)=O)CCCC1)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.I Straub, et al. Citrus fruit and fabacea secondary metabolites potently and selectively block TRPM3. Br J Pharmacol. 2013 Apr;168(8):1835-50.
molnova catalog
related products
  • BDP9066

    BDP9066 is a potent and selective MRCK inhibitor that inhibits MRCKβ and MRCKα/β and can be used for the prevention and treatment of skin cancer.

  • ROCK-IN-5

    ROCK-IN-5 (compound I-B-37) is a potent inhibitor of protein kinases, including ROCK, ERK, GSK, and AGC, with potential applications in cardiac, proliferative, and neurodegenerative disease research.

  • Thiazovivin

    Thiazovivin (Tzv) is a novel ROCK inhibitor with IC50 of 0.5 μM, promotes hESC survival after single-cell dissociation.